title: Hepatitis B reactivation and current clinical impact.
abstract: Hepatitis B virus (HBV) reactivation results from increased viral replication in inactive carriers or patients with prior infection with HBV. Reactivation may occur spontaneously or secondary to immunomodulating or immunosuppressive chemotherapy. Reactivation may manifest with no symptoms but on occasion results in acute or even severe acute hepatitis. Prevention is the best management approach, hence HBV screening using serology should be performed for all patients undergoing any immunomodulating, immunosuppressive or chemotherapeutic treatment. Antiviral prophylaxis has proven effective in inactive carriers and in some patients with former infection with HBV undergoing selected immunosuppressive therapies.
authors.affiliation: Servicio de Gastroenterología y Hepatología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Universidad Autónoma de Madrid, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Alvarez-Suárez
authors.forename: J
authors.initials: J
authors.lastname: de-la-Revilla-Negro
authors.forename: B
authors.initials: B
authors.lastname: Ruiz-Antorán
authors.forename: J L
authors.initials: JL
authors.lastname: Calleja-Panero
mesh_terms: D000465:Algorithms; D001691:Biological Therapy; D006509:Hepatitis B / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D012008:Recurrence; D012307:Risk Factors